Recent news on Gemtuzumab Ozogamicin

Gemtuzumab Ozogamicin Boosts Effects of Arsenic Trioxide in High ...  -  May 22, 2007
DG NewsTherefore, Dr. Sekeres and colleagues conducted a trial in which they evaluated a combination arsenic trioxide and gemtuzumab ozogamicin (Mylotarg®) in

Lonza plans to commercially produce emerging class of drugs  -  May 10, 2007
DrugResearcher.com,Currently, there is only one antibody-drug conjugate on the market, which is Mylotarg (gemtuzumab ozogamicin) manufactured by Wyeth.

T cell antibodies to treat diabetes  -  Apr 10, 2007
LabTechnologist.com,If, in the future, they decided to resurrect this research, Dr MacKenzie pointed to Wyeth's Mylotarg (gemtuzumab ozogamicin) product as an example of how it

Wyeth buys out Takeda's 20% stake in Japanese unit  -  Apr 4, 2007
Pharma Times (subscription),It was noted that Mylotarg (gemtuzumab ozogamicin), a humanised anti-CD33 monoclonal antibody indicated for the treatment of acute myeloid leukaemia,

Mylotarg® May Decrease Relapse Rate in Patients with Newly ...  -  18 Jan 2007
Cancer Consultants (press release),Researchers affiliated with the MRC AML 15 trial have reported that the addition of Mylotarg (gemtuzumab ozogamicin) to one of three different induction

Mylotarg® and Vidaza® Effective for Elderly Patients with AML or MDS  -  18 Jan 2007
Cancer Consultants (press release),Researchers from Loyola University have reported that the combination of Mylotarg® (gemtuzumab ozogamicin) and Vidaza® (azacitidine) produces a high rate of

Gemtuzumab Induction Therapy Improved Progression Free Survival ...  -  Dec 14, 2006
DG NewsORLANDO, FL -- December 14, 2006 -- The immunoconjugate gemtuzumab ozogamicin in addition to standard chemotherapy appears to improve outcomes in patients

ASH: Mylotarg Boosts AML Disease-Free Survival  -  Dec 12, 2006
MedPage Today,...without the addition of Mylotarg (gemtuzumab ozogamicin) showed that patients who received the antibody had significantly better disease-free survival,

Clinical Data on Pharmion's Epigenetic Therapies in Higher-Risk ...  -  Dec 7, 2006
Earthtimes.orgAzacitidine Plus Gemtuzumab Ozogamicin (GO): A Novel Combination in the Treatment of AML and High-Risk MDS in the Elderly Abstract ID: 1981 Sucha Nand,

Bioenvision’s Evoltra ® Data Selected for Oral Presentation at ASH ...  -  Dec 4, 2006
Business Wire (press release),Leukemia Poster Board #37-II Abstract 1950 The Feasibility of Combining Daunorubicin, Clofarabine and Gemtuzumab Ozogamicin Is Feasible and Effective.

Increased Use of Wyeth's Mylotarg and Launches of New Drugs Will ...  Oct 16, 2006
...pharmaceutical and healthcare issues, finds that the launch of novel, premium-priced drugs and the progression of Wyeth's Mylotarg (gemtuzumab ozogamicin) to a ... -PR Newswire (press release), -- Mitchel L. Zoler  Sep 18, 2006
He helped design the studies that made the drug gemtuzumab ozogamicin (Mylotarg) available to patients with acute myeloid leukemia. ... -Philadelphia Jewish Voice

ASH: Mylotarg Boosts AML Disease-Free Survival  -  12 Dec 2006
MedPage Today,...without the addition of Mylotarg (gemtuzumab ozogamicin) showed that patients who received the antibody had significantly better disease-free survival,

Clinical Data on Pharmion's Epigenetic Therapies in Higher-Risk ...  -  Dec 7, 2006
Earthtimes.orgAzacitidine Plus Gemtuzumab Ozogamicin (GO): A Novel Combination in the Treatment of AML and High-Risk MDS in the Elderly Abstract ID: 1981 Sucha Nand,

Bioenvision’s Evoltra ® Data Selected for Oral Presentation at ASH ...  -  Dec 4, 2006
Business Wire (press release),Leukemia Poster Board #37-II Abstract 1950 The Feasibility of Combining Daunorubicin, Clofarabine and Gemtuzumab Ozogamicin Is Feasible and Effective.



Acceleron Pharma Appoints Matthew L. Sherman, MD as Chief Medical ...  16 May 2006
...projects for both small molecule and biologic therapeutics, including the submission and approval of Mylotarg(R) (gemtuzumab ozogamicin for injection) by the ... - Genetic Engineering News

Pediatric acute myeloid leukaemia: accurate prediction of ...  Jan 14, 2006
Patients found to have no response to ADE during induction therapy were subsequently treated with low-dose ADE plus Gemtuzumab ozogamicin, while all others ... - Xagena.it

This site is for informational purposes only--it does not offer medical advice or sell health products. If you need assistance, contact your physician or healthcare professional